Moderate

Total intravenous anaesthesia (TIVA) & target-controlled infusion

Anaesthetic technique · Perioperative & Anaesthesia
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

Maintenance of anaesthesia using intravenous agents (usually propofol with an opioid) delivered by target-controlled infusion (TCI) pumps that model plasma or effect-site concentration. Indications include tubeless/shared-airway surgery, MH susceptibility, PONV reduction, neuromonitoring and transfers.

Red flags

  • Rising depth-monitor index or clinical signs of lightness during paralysis (risk of awareness)
  • Infusion site swelling, resistance or disconnection — drug not reaching the patient
  • Profound unexplained hypotension suggesting relative overdose
  • Propofol infusion syndrome features on prolonged high-dose ICU infusions

Assessment

Differential diagnosis

  • Awareness due to interrupted/insufficient infusion (lightness)
  • Overdose/relative overdose causing hypotension
  • Pump malfunction, line disconnection or tissued cannula
  • Pharmacokinetic variability — elderly, obese, low cardiac output
  • Confusion with volatile technique needs (MH risk, scavenging)

Investigations

  • Continuous processed EEG (depth of anaesthesia) monitoring — strongly recommended when neuromuscular blockade is used
  • Visual confirmation of a patent, visible IV line dedicated to the TIVA infusion
  • Haemodynamic monitoring (invasive arterial line for major cases)
  • Infusion pump data log / TCI model and target concentration display

Management

  • Select an appropriate TCI model: Marsh or Schnider for propofol; adjust for age and weight (use lean/adjusted body weight appropriately)
  • Site a dedicated, visible cannula with an antireflux and antisiphon valve; keep the infusion site in view
  • Induce to effect-site target (e.g. propofol effect-site 4-6 microgram/mL) with a remifentanil TCI/opioid co-administration
  • Apply processed EEG monitoring and titrate to target index while correlating with clinical signs
  • Maintain the infusion continuously — never pause for transfer without a plan; watch for disconnection
  • Titrate to surgical stimulus and haemodynamics; treat hypotension with fluids/vasopressors rather than abrupt large dose cuts that risk awareness
  • At emergence, stop infusions and allow context-sensitive decrement; ensure adequate analgesia established before remifentanil stops
  • Document infusion targets, total doses and depth-monitoring values

Drugs & doses

Propofol 1% or 2% — TCI effect-site target 4-6 microgram/mL (Schnider), titrated to depth monitor and clinical response
Remifentanil — TCI effect-site target 2-6 ng/mL, titrated to stimulus (short context-sensitive half-time)
Alternative opioid — Fentanyl 1-3 microgram/kg IV boluses if remifentanil not used
Lidocaine 0.5-1 mg/kg IV at induction to reduce propofol injection pain

Disposition

Routine recovery in PACU with standard monitoring; depth-monitor and infusion documentation retained, and awareness concerns followed up per local AAGA pathway.

Complications & pitfalls

  • Accidental awareness under general anaesthesia from infusion failure
  • Haemodynamic instability/hypotension
  • Extravasation and failure of drug delivery
  • Delayed emergence with inappropriate high targets
  • Propofol-related infusion syndrome (prolonged, high-dose use)

Exam pearls

  • Keep the infusion line and cannula visible at all times — a hidden tissued cannula is a leading cause of awareness
  • TCI predicts, it does not measure — use processed EEG, especially when neuromuscular blockade masks movement
  • Remifentanil offloads propofol requirement but offers no residual analgesia; establish longer-acting analgesia before stopping it
  • TIVA is the technique of choice for MH-susceptible patients and reduces PONV versus volatile
  • Antireflux and antisiphon valves and a dedicated line prevent catastrophic bolus or backflow

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.